|
1
|
Shaw J, Harvey C, Richards C and Kim C:
Temporal trends in treatment and survival of older adult diffuse
large B-Cell lymphoma patients in the SEER-Medicare linked
database. Leuk Lymphoma. 60:3235–3243. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chiappella A and Vitolo U: Lenalidomide in
diffuse large B-cell lymphomas. Adv Hematol. 2012:4983422012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohmachi K: Diffuse large B-cell lymphoma:
Standard treatment and research questions. Rinsho Ketsueki.
60:1193–1198. 2019.(In Japanese). PubMed/NCBI
|
|
4
|
Yamaguchi M: Current status and future
prospects of diffuse large B-cell lymphoma treatment. Rinsho
Ketsueki. 63:1126–1134. 2022.(In Japanese). PubMed/NCBI
|
|
5
|
Murakami Y, Matsumoto K, Miyake M, Amano
N, Shimura S, Nishimura N, Iida K, Matsushita Y, Abe T, Yamada T,
et al: Real-world treatment patterns and oncological outcomes in
early relapse and refractory disease after bacillus Calmette-Guérin
failure in non-muscle-invasive bladder cancer. Int J Urol.
29:1195–1203. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
George H, Gunawardana J, Keane C, Hicks RJ
and Gandhi MK: A coordinated strategy for a simple, pragmatic
approach to the early identification of the ultra-high-risk patient
with diffuse large B-cell lymphoma. Intern Med J. 53:1105–1109.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zahid U, Akbar F, Amaraneni A, Husnain M,
Chan O, Riaz IB, McBride A, Iftikhar A and Anwer F: A review of
autologous stem cell transplantation in lymphoma. Curr Hematol
Malig Rep. 12:217–226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimoni A and Zwas ST: Radioimmunotherapy
and autologous stem-cell transplantation in the treatment of B-cell
non-hodgkin lymphoma. Semin Nucl Med. 46:119–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ting CY, Gan GG, Ong DBL, Tan SY and Bee
PC: Extranodal site of diffuse large B-cell lymphoma and the risk
of R-CHOP chemotherapy resistance and early relapse. Int J Clin
Pract. 74:e135942020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Récher C, Coiffier B, Haioun C, Molina TJ,
Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G,
Morschhauser F, et al: Intensified chemotherapy with ACVBP plus
rituximab versus standard CHOP plus rituximab for the treatment of
diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised
phase 3 trial. Lancet. 378:1858–1867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cunningham D, Hawkes EA, Jack A, Qian W,
Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A,
et al: Rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisolone in patients with newly diagnosed diffuse large
B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose
intensification with 14-day versus 21-day cycles. Lancet.
381:1817–1826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Delarue R, Tilly H, Mounier N, Petrella T,
Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M,
Fruchart C, et al: Dose-dense rituximab-CHOP compared with standard
rituximab-CHOP in elderly patients with diffuse large B-cell
lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet
Oncol. 14:525–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartlett NL, Wilson WH, Jung SH, Hsi ED,
Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS,
et al: Dose-Adjusted EPOCH-R compared with R-CHOP as frontline
therapy for diffuse large B-Cell lymphoma: Clinical outcomes of the
phase III intergroup trial alliance/CALGB 50303. J Clin Oncol.
37:1790–1799. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sehn LH, Martelli M, Trněný M, Liu W,
Bolen CR, Knapp A, Sahin D, Sellam G and Vitolo U: A randomized,
open-label, phase III study of obinutuzumab or rituximab plus CHOP
in patients with previously untreated diffuse large B-Cell
lymphoma: Final analysis of GOYA. J Hematol Oncol. 13:712020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melchardt T, Hufnagl C, Weinstock DM, Kopp
N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G,
Hartmann TN, et al: Clonal evolution in relapsed and refractory
diffuse large B-cell lymphoma is characterized by high dynamics of
subclones. Oncotarget. 7:51494–51502. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morin RD, Mendez-Lago M, Mungall AJ, Goya
R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field
M, et al: Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature. 476:298–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Isshiki Y, Chen X, Teater M, Karagiannidis
I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J, et al: EZH2
inhibition enhances T cell immunotherapies by inducing lymphoma
immunogenicity and improving T cell function. Cancer Cell.
43:49–68.e9. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morschhauser F, Salles G, McKay P, Tilly
H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson MJ,
Fruchart C, et al: Interim report from a phase 2 multicenter study
of tazemetostat, an ezh2 inhibitor, in patients with relapsed or
refractory b-cell non-hodgkin lymphomas. Hematological Oncology.
35:24–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brach D, Johnston-Blackwell D, Drew A,
Lingaraj T, Motwani V, Warholic NM, Feldman I, Plescia C, Smith JJ,
Copeland RA, et al: EZH2 inhibition by tazemetostat results in
altered dependency on B-cell activation signaling in DLBCL. Mol
Cancer Ther. 16:2586–2597. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McCabe MT, Ott HM, Ganji G, Korenchuk S,
Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III,
Diaz E, et al: EZH2 inhibition as a therapeutic strategy for
lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bisserier M and Wajapeyee N: Mechanisms of
resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Blood. 131:2125–2137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baker T, Nerle S, Pritchard J, Zhao B,
Rivera VM, Garner A and Gonzalvez F: Acquisition of a single EZH2
D1 domain mutation confers acquired resistance to EZH2-targeted
inhibitors. Oncotarget. 6:32646–32655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gibaja V, Shen F, Harari J, Korn J, Ruddy
D, Saenz-Vash V, Zhai H, Rejtar T, Paris CG, Yu Z, et al:
Development of secondary mutations in wild-type and mutant EZH2
alleles cooperates to confer resistance to EZH2 inhibitors.
Oncogene. 35:558–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tula-Sanchez AA, Havas AP, Alonge PJ,
Klein ME, Doctor SR, Pinkston W, Glinsmann-Gibson BJ, Rimsza LM and
Smith CL: A model of sensitivity and resistance to histone
deacetylase inhibitors in diffuse large B cell lymphoma: Role of
cyclin-dependent kinase inhibitors. Cancer Biol Ther. 14:949–961.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Joosten M, Ginzel S, Blex C, Schmidt D,
Gombert M, Chen C, Linka RM, Gräbner O, Hain A, Hirsch B, et al: A
novel approach to detect resistance mechanisms reveals FGR as a
factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.
Mol Oncol. 10:1232–1244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beielstein AC and Pallasch CP: Tumor
metabolism as a regulator of tumor-host interactions in the B-cell
lymphoma microenvironment-fueling progression and novel brakes for
therapy. Int J Mol Sci. 20:41582019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Young RM, Phelan JD, Wilson WH and Staudt
LM: Pathogenic B-cell receptor signaling in lymphoid malignancies:
New insights to improve treatment. Immunol Rev. 291:190–213. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ondrisova L and Mraz M: Genetic and
non-genetic mechanisms of resistance to BCR signaling inhibitors in
B cell malignancies. Front Oncol. 10:5915772020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Phelan JD, Young RM, Webster DE, Roulland
S, Wright GW, Kasbekar M, Shaffer AL III, Ceribelli M, Wang JQ,
Schmitz R, et al: A multiprotein supercomplex controlling oncogenic
signalling in lymphoma. Nature. 560:387–391. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fontan L, Yang C, Kabaleeswaran V, Volpon
L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R,
Yang SN, et al: MALT1 small molecule inhibitors specifically
suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 22:812–824.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang WG, Cui WL, Wang L, Zhu F, Wan XC,
Ping B, Zhou XY and Li XQ: Loss of B-cell receptor expression
defines a subset of diffuse large B-cell lymphoma characterized by
silent BCR/PI3K/AKT signaling and a germinal center phenotype
displaying low-risk clinicopathologic features. Am J Surg Pathol.
39:902–911. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turturro F: Constitutive NF-κ B activation
underlines major mechanism of drug resistance in relapsed
refractory diffuse large B cell lymphoma. Biomed Res Int.
2015:4845372015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Davis RE, Ngo VN, Lenz G, Tolar P, Young
RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al:
Chronic active B-cell-receptor signalling in diffuse large B-cell
lymphoma. Nature. 463:88–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam
GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, et al: NF-κB
p50 activation associated with immune dysregulation confers poorer
survival for diffuse large B-cell lymphoma patients with wild-type
p53. Mod Pathol. 30:854–876. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Minderman M, Lantermans HC, Grüneberg LJ,
Cillessen S, Bende RJ, van Noesel CJM, Kersten MJ, Pals ST and
Spaargaren M: MALT1-dependent cleavage of CYLD promotes NF-κB
signaling and growth of aggressive B-cell receptor-dependent
lymphomas. Blood Cancer J. 13:372023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wilson WH, Young RM, Schmitz R, Yang Y,
Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano
J, et al: Targeting B cell receptor signaling with ibrutinib in
diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fox LC, Yannakou CK, Ryland G, Lade S,
Dickinson M, Campbell BA and Prince HM: Molecular mechanisms of
disease progression in primary cutaneous diffuse large B-cell
lymphoma, leg type during ibrutinib therapy. Int J Mol Sci.
19:17582018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis
N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, et al:
BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects
BTK(wild-type) MYD88-mutated cells by a paracrine mechanism. Blood.
131:2047–2059. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi J, Phelan JD, Wright GW, Häupl B,
Huang DW, Shaffer AL III, Young RM, Wang Z, Zhao H, Yu X, et al:
Regulation of B cell receptor-dependent NF-κB signaling by the
tumor suppressor KLHL14. Proc Natl Acad Sci USA. 117:6092–6102.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pasqualucci L: Epigenetic rewiring of BCR
signaling as a novel mechanism of ibrutinib resistance in
ABC-DLBCL. Blood Cancer Discov. 2:555–558. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jain N, Singh S, Laliotis G, Hart A,
Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM,
Sircar A, et al: Targeting phosphatidylinositol 3 kinase-β and -δ
for Bruton tyrosine kinase resistance in diffuse large B-cell
lymphoma. Blood Adv. 4:4382–4392. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sarbassov DD, Ali SM and Sabatini DM:
Growing roles for the mTOR pathway. Curr Opin Cell Biol.
17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim
D, Al-Dayel F, Bavi P and Al-kuraya KS: Leptin receptor expression
and its association with PI3K/AKT signaling pathway in diffuse
large B-cell lymphoma. Leuk Lymphoma. 51:1305–1314. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pfeifer M, Grau M, Lenze D, Wenzel SS,
Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, et
al: PTEN loss defines a PI3K/AKT pathway-dependent germinal center
subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA.
110:12420–12425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang X, Cao X, Sun R, Tang C, Tzankov A,
Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, et al: Clinical
significance of PTEN deletion, mutation, and loss of PTEN
expression in de novo diffuse large B-cell lymphoma. Neoplasia.
20:574–593. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song L, Xiong H, Li J, Liao W, Wang L, Wu
J and Li M: Sphingosine kinase-1 enhances resistance to apoptosis
through activation of PI3K/Akt/NF-κB pathway in human non-small
cell lung cancer. Clin Cancer Res. 17:1839–1849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu D, Liu L, Li H, Huang Z and Wang Y:
Sphingosine kinase 1 counteracts chemosensitivity and immune
evasion in diffuse large B cell lymphoma cells via the
PI3K/AKT/PD-L1 axis. Int Immunopharmacol. 143:1133612024.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hou CX, Wang L, Cai M, Meng Y, Tang YT,
Zhu QH, Han W, Sun NN, Ma B, Hu Y and Ye JH: Sphk1 promotes
salivary adenoid cystic carcinoma progression via PI3K/Akt
signaling. Pathol Res Pract. 227:1536202021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hasselblom S, Hansson U, Olsson M, Torén
L, Bergström A, Nilsson-Ehle H and Andersson PO: High
immunohistochemical expression of p-AKT predicts inferior survival
in patients with diffuse large B-cell lymphoma treated with
immunochemotherapy. Br J Haematol. 149:560–568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kane LP, Shapiro VS, Stokoe D and Weiss A:
Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol. 9:601–604.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
García MG, Alaniz LD, Russo RI, Alvarez E
and Hajos SE: PI3K/Akt inhibition modulates multidrug resistance
and activates NF-kappaB in murine lymphoma cell lines. Leuk Res.
33:288–296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gupta M, Ansell SM, Novak AJ, Kumar S,
Kaufmann SH and Witzig TE: Inhibition of histone deacetylase
overcomes rapamycin-mediated resistance in diffuse large B-cell
lymphoma by inhibiting Akt signaling through mTORC2. Blood.
114:2926–2935. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Smith SM, van Besien K, Karrison T, Dancey
J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, et
al: Temsirolimus has activity in non-mantle cell non-Hodgkin's
lymphoma subtypes: The University of Chicago phase II consortium. J
Clin Oncol. 28:4740–4746. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Eyre TA, Hildyard C, Hamblin A, Ali AS,
Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, et
al: A phase II study to assess the safety and efficacy of the dual
mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Hematol Oncol. 37:352–359. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Eyre TA, Collins GP, Goldstone AH and
Cwynarski K: Time now to TORC the TORC? New developments in mTOR
pathway inhibition in lymphoid malignancies. Br J Haematol.
166:336–351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Calò V, Migliavacca M, Bazan V, Macaluso
M, Buscemi M, Gebbia N and Russo A: STAT proteins: from normal
control of cellular events to tumorigenesis. J Cell Physiol.
197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huang X, Meng B, Iqbal J, Ding BB, Perry
AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, et al: Activation
of the STAT3 signaling pathway is associated with poor survival in
diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol.
31:4520–4528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Park YH, Sohn SK, Kim JG, Lee MH, Song HS,
Kim MK, Jung JS, Lee JJ, Kim HJ and Kim DH: Interaction between
BCL2 and interleukin-10 gene polymorphisms alter outcomes of
diffuse large B-cell lymphoma following rituximab plus CHOP
chemotherapy. Clin Cancer Res. 15:2107–2115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Reilley MJ, McCoon P, Cook C, Lyne P,
Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, et
al: STAT3 antisense oligonucleotide AZD9150 in a subset of patients
with heavily pretreated lymphoma: results of a phase 1b trial. J
Immunother Cancer. 6:1192018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Roschewski M, Patel MR, Reagan PM, Saba
NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K,
et al: Phase I study of acalabrutinib plus danvatirsen (AZD9150) in
relapsed/refractory diffuse large B-Cell lymphoma including
circulating tumor DNA biomarker assessment. Clin Cancer Res.
29:3301–3312. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Béguelin W, Sawh S, Chambwe N, Chan FC,
Jiang Y, Choo JW, Scott DW, Chalmers A, Geng H, Tsikitas L, et al:
IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia.
29:1684–1694. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cao Y, Li Z, Mao L, Cao H, Kong J, Yu B,
Yu C and Liao W: The use of proteomic technologies to study
molecular mechanisms of multidrug resistance in cancer. Eur J Med
Chem. 162:423–434. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Braconi L, Teodori E, Riganti C,
Coronnello M, Nocentini A, Bartolucci G, Pallecchi M, Contino M,
Manetti D, Romanelli MN, et al: New dual P-Glycoprotein (P-gp) and
human carbonic anhydrase XII (hCA XII) inhibitors as multidrug
resistance (MDR) reversers in cancer cells. J Med Chem.
65:14655–14672. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: From genomics to mechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kerb R, Hoffmeyer S and Brinkmann U: ABC
drug transporters: Hereditary polymorphisms and pharmacological
impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2:51–64. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kim JE, Singh RR, Cho-Vega JH, Drakos E,
Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ and Vega F: Sonic
hedgehog signaling proteins and ATP-binding cassette G2 are
aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol.
221:1312–1320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ohsawa M, Ikura Y, Fukushima H, Shirai N,
Sugama Y, Suekane T, Hirayama M, Hino M and Ueda M:
Immunohistochemical expression of multidrug resistance proteins as
a predictor of poor response to chemotherapy and prognosis in
patients with nodal diffuse large B-cell lymphoma. Oncology.
68:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Muris JJ, Meijer CJ, Ossenkoppele GJ, Vos
W and Oudejans JJ: Apoptosis resistance and response to
chemotherapy in primary nodal diffuse large B-cell lymphoma.
Hematol Oncol. 24:97–104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Klanova M and Klener P: BCL-2 proteins in
pathogenesis and therapy of B-Cell non-hodgkin lymphomas. Cancers
(Basel). 12:9382020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Donati G, Ravà M, Filipuzzi M, Nicoli P,
Cassina L, Verrecchia A, Doni M, Rodighiero S, Parodi F, Boletta A,
et al: Targeting mitochondrial respiration and the BCL2 family in
high-grade MYC-associated B-cell lymphoma. Mol Oncol. 16:1132–1152.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ennishi D, Mottok A, Ben-Neriah S, Shulha
HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, et
al: Genetic profiling of MYC and BCL2 in diffuse large B-cell
lymphoma determines cell-of-origin-specific clinical impact. Blood.
129:2760–2770. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kondo E and Yoshino T: Expression of
apoptosis regulators in germinal centers and germinal
center-derived B-cell lymphomas: Insight into B-cell
lymphomagenesis. Pathol Int. 57:391–397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Souers AJ, Leverson JD, Boghaert ER,
Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH,
Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2
inhibitor, achieves antitumor activity while sparing platelets. Nat
Med. 19:202–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Davids MS, Roberts AW, Seymour JF, Pagel
JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH,
et al: Phase I first-in-human study of venetoclax in patients with
relapsed or refractory non-hodgkin lymphoma. J Clin Oncol.
35:826–833. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Choudhary GS, Al-Harbi S, Mazumder S, Hill
BT, Smith MR, Bodo J, Hsi ED and Almasan A: MCL-1 and
BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be
overcome by preventing PI3K/AKT/mTOR activation in lymphoid
malignancies. Cell Death Dis. 6:e15932015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Adams CM, Mitra R, Gong JZ and Eischen CM:
Non-Hodgkin and hodgkin lymphomas select for overexpression of
BCLW. Clin Cancer Res. 23:7119–7129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yecies D, Carlson NE, Deng J and Letai A:
Acquired resistance to ABT-737 in lymphoma cells that up-regulate
MCL-1 and BFL-1. Blood. 115:3304–3313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Setiawan SA, Liu WZ, Weng PW, Lee CH,
Yadav VK, Hardianti MS, Yeh CT and Chao TY: Synergistic disruption
of BTK and BCL-2 causes apoptosis while inducing ferroptosis in
double-hit lymphoma. Eur J Pharmacol. 943:1755262023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Albershardt TC, Salerni BL, Soderquist RS,
Bates DJ, Pletnev AA, Kisselev AF and Eastman A: Multiple BH3
mimetics antagonize antiapoptotic MCL1 protein by inducing the
endoplasmic reticulum stress response and up-regulating BH3-only
protein NOXA. J Biol Chem. 286:24882–24895. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wenzel SS, Grau M, Mavis C, Hailfinger S,
Wolf A, Madle H, Deeb G, Dörken B, Thome M, Lenz P, et al: MCL1 is
deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia. 27:1381–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Fernández-Marrero Y, Spinner S, Kaufmann T
and Jost PJ: Survival control of malignant lymphocytes by
anti-apoptotic MCL-1. Leukemia. 30:2152–2159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cho-Vega JH, Rassidakis GZ, Admirand JH,
Oyarzo M, Ramalingam P, Paraguya A, McDonnell TJ, Amin HM and
Medeiros LJ: MCL-1 expression in B-cell non-Hodgkin's lymphomas.
Hum Pathol. 35:1095–1100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Carter BZ, Mak PY, Tao W, Ayoub E,
Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V,
et al: Combined inhibition of BCL-2 and MCL-1 overcomes BAX
deficiency-mediated resistance of TP53-mutant acute myeloid
leukemia to individual BH3 mimetics. Blood Cancer J. 13:572023.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Smith VM, Dietz A, Henz K, Bruecher D,
Jackson R, Kowald L, van Wijk SJL, Jayne S, Macip S, Fulda S, et
al: Specific interactions of BCL-2 family proteins mediate
sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
Haematologica. 105:2150–2163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li L, Pongtornpipat P, Tiutan T, Kendrick
SL, Park S, Persky DO, Rimsza LM, Puvvada SD and Schatz JH:
Synergistic induction of apoptosis in high-risk DLBCL by BCL2
inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Leukemia. 29:1702–1712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Xerri L, Parc P, Brousset P, Schlaifer D,
Hassoun J, Reed JC, Krajewski S and Birnbaum D: Predominant
expression of the long isoform of Bcl-x (Bcl-xL) in human
lymphomas. Br J Haematol. 92:900–906. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Klanova M, Andera L, Brazina J, Svadlenka
J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman
K, et al: Targeting of BCL2 family proteins with ABT-199 and
homoharringtonine reveals BCL2- and MCL1-dependent subgroups of
diffuse large B-Cell lymphoma. Clin Cancer Res. 22:1138–1149. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Rys RN, Wever CM, Geoffrion D, Goncalves
C, Ghassemian A, Brailovski E, Ryan J, Stoica L, Hébert J,
Petrogiannis-Haliotis T, et al: Apoptotic blocks in primary
non-hodgkin B cell lymphomas identified by BH3 profiling. Cancers
(Basel). 13:10222021. View Article : Google Scholar
|
|
91
|
Willimott S, Merriam T and Wagner SD:
Apoptosis induces Bcl-XS and cleaved Bcl-XL in chronic lymphocytic
leukaemia. Biochem Biophys Res Commun. 405:480–485. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Print CG, Loveland KL, Gibson L, Meehan T,
Stylianou A, Wreford N, de Kretser D, Metcalf D, Köntgen F, Adams
JM and Cory S: Apoptosis regulator bcl-w is essential for
spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci
USA. 95:12424–12431. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ross AJ, Waymire KG, Moss JE, Parlow AF,
Skinner MK, Russell LD and MacGregor GR: Testicular degeneration in
Bclw-deficient mice. Nat Genet. 18:251–256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Adams CM, Kim AS, Mitra R, Choi JK, Gong
JZ and Eischen CM: BCL-W has a fundamental role in B cell survival
and lymphomagenesis. J Clin Invest. 127:635–650. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Diepstraten ST, Chang C, Tai L, Gong JN,
Lan P, Dowell AC, Taylor GS, Strasser A and Kelly GL: BCL-W is
dispensable for the sustained survival of select Burkitt lymphoma
and diffuse large B-cell lymphoma cell lines. Blood Adv. 4:356–366.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Schimmer AD: Inhibitor of apoptosis
proteins: Translating basic knowledge into clinical practice.
Cancer Res. 64:7183–7190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed
SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP and
Al-Kuraya KS: Prognostic significance of XIAP expression in DLBCL
and effect of its inhibition on AKT signalling. J Pathol.
222:180–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Engel K, Rudelius M, Slawska J, Jacobs L,
Abhari BA, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V,
Brunner A, et al: USP9X stabilizes XIAP to regulate mitotic cell
death and chemoresistance in aggressive B-cell lymphoma. EMBO Mol
Med. 8:851–862. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Akyurek N, Ren Y, Rassidakis GZ, Schlette
EJ and Medeiros LJ: Expression of inhibitor of apoptosis proteins
in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer. 107:1844–1851.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang Y, Wang J, Sui X, Li Y, Lu K, Fang
X, Jiang Y and Wang X: Prognostic and clinicopathological value of
survivin in diffuse large B-cell lymphoma: A meta-analysis.
Medicine (Baltimore). 94:e14322015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Cheson BD, Bartlett NL, Vose JM,
Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S and Papadopoulos
KP: A phase II study of the survivin suppressant YM155 in patients
with refractory diffuse large B-cell lymphoma. Cancer.
118:3128–3134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kita A, Mitsuoka K, Kaneko N, Nakata M,
Yamanaka K, Jitsuoka M, Miyoshi S, Noda A, Mori M, Nakahara T and
Sasamata M: Sepantronium bromide (YM155) enhances response of human
B-cell non-Hodgkin lymphoma to rituximab. J Pharmacol Exp Ther.
343:178–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Nowakowski GS, Zhu J, Zhang Q, Brody J,
Sun X, Maly J, Song Y, Rizvi S, Song Y, Lansigan F, et al: ENGINE:
A Phase III randomized placebo controlled study of
enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large
B-cell lymphoma patients with the genomic biomarker DGM1. Future
Oncol. 16:991–999. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hainsworth JD, Arrowsmith ER, McCleod M,
Hsi ED, Hamid O, Shi P, Lin BK and Fayad LE: A randomized, phase 2
study of R-CHOP plus enzastaurin vs R-CHOP in patients with
intermediate- or high-risk diffuse large B-cell lymphoma. Leuk
Lymphoma. 57:216–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Jiang D, Mo Q, Sun X, Wang X, Dong M,
Zhang G, Chen F and Zhao Q: Pyruvate dehydrogenase kinase
4-mediated metabolic reprogramming is involved in rituximab
resistance in diffuse large B-cell lymphoma by affecting the
expression of MS4A1/CD20. Cancer Sci. 112:3585–3597. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wu X, Ban C, Deng W, Bao X, Tang N, Wu Y,
Deng Z, Xiong J and Zhao Q: Unveiling the PDK4-centered
rituximab-resistant mechanism in DLBCL: the potential of the
‘Smart’ exosome nanoparticle therapy. Mol Cancer. 23:1442024.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Narkhede M, Tomassetti S, Iqbal M, Tin A,
Rivero-Hinojosa S, George GV, Widden H, Benrud R, Malhotra M,
Rodriguez A and Liu MC: Tumor-informed ctDNA assessment as a
valuable prognostic and predictive biomarker in diffuse large
B-cell lymphoma. Front Oncol. 14:14070032024. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wu FT, Lu L, Xu W and Li JY: Circulating
tumor DNA: Clinical roles in diffuse large B cell lymphoma. Ann
Hematol. 98:255–269. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Xu-Monette ZY, Wu L, Visco C, Tai YC,
Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et
al: Mutational profile and prognostic significance of TP53 in
diffuse large B-cell lymphoma patients treated with R-CHOP: Report
from an International DLBCL rituximab-CHOP consortium program
study. Blood. 120:3986–3996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang JY, Zhang PP, Zhou WP, Yu JY, Yao
ZH, Chu JF, Yao SN, Wang C, Lone W, Xia QX, et al: L-Type Cav 1.2
calcium channel-α-1C regulates response to rituximab in diffuse
large B-cell lymphoma. Clin Cancer Res. 25:4168–4178. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Bhome R, Bullock MD, Al Saihati HA, Goh
RW, Primrose JN, Sayan AE and Mirnezami AH: A top-down view of the
tumor microenvironment: Structure, cells and signaling. Front Cell
Dev Biol. 3:332015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro-environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Mraz M, Zent CS, Church AK, Jelinek DF, Wu
X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE and
Nowakowski GS: Bone marrow stromal cells protect lymphoma B-cells
from rituximab-induced apoptosis and targeting integrin α-4-β-1
(VLA-4) with natalizumab can overcome this resistance. Br J
Haematol. 155:53–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yin H, Zhong F, Ouyang Y, Wang Q, Ding L
and He S: Upregulation of ADAM12 contributes to accelerated cell
proliferation and cell adhesion-mediated drug resistance (CAM-DR)
in Non-Hodgkin's Lymphoma. Hematology. 22:527–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Lwin T, Crespo LA, Wu A, Dessureault S,
Shu HB, Moscinski LC, Sotomayor E, Dalton WS and Tao J: Lymphoma
cell adhesion-induced expression of B cell-activating factor of the
TNF family in bone marrow stromal cells protects non-Hodgkin's B
lymphoma cells from apoptosis. Leukemia. 23:170–177. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Lwin T, Hazlehurst LA, Li Z, Dessureault
S, Sotomayor E, Moscinski LC, Dalton WS and Tao J: Bone marrow
stromal cells prevent apoptosis of lymphoma cells by upregulation
of anti-apoptotic proteins associated with activation of NF-kappaB
(RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 21:1521–1531.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lwin T, Lin J, Choi YS, Zhang X, Moscinski
LC, Wright KL, Sotomayor EM, Dalton WS and Tao J: Follicular
dendritic cell-dependent drug resistance of non-Hodgkin lymphoma
involves cell adhesion-mediated Bim down-regulation through
induction of microRNA-181a. Blood. 116:5228–5236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lwin T, Zhao X, Cheng F, Zhang X, Huang A,
Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, et al: A
microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop
in non-Hodgkin B cell lymphomas. J Clin Invest. 123:4612–4626.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ,
Manyam GC, de Winde CM, van den Brand M, Tzankov A, Visco C, Wang
J, et al: Assessment of CD37 B-cell antigen and cell of origin
significantly improves risk prediction in diffuse large B-cell
lymphoma. Blood. 128:3083–3100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kiyasu J, Miyoshi H, Hirata A, Arakawa F,
Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, et al:
Expression of programmed cell death ligand 1 is associated with
poor overall survival in patients with diffuse large B-cell
lymphoma. Blood. 126:2193–2201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Advani R, Flinn I, Popplewell L, Forero A,
Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP,
et al: CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's
lymphoma. N Engl J Med. 379:1711–1721. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Linderoth J, Edén P, Ehinger M, Valcich J,
Jerkeman M, Bendahl PO, Berglund M, Enblad G, Erlanson M, Roos G
and Cavallin-Ståhl E: Genes associated with the tumour
microenvironment are differentially expressed in cured versus
primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J
Haematol. 141:423–432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Falchi L, Vardhana SA and Salles GA:
Bispecific antibodies for the treatment of B-cell lymphoma:
Promises, unknowns, and opportunities. Blood. 141:467–480. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Esquinas E, Moreno-Sanz A, Sandá V,
Stodulski-Ciesla D, Borregón J, Peña-Blanque V, Fernández-Calles J,
Fernandez-Fuentes N, Serrano-Lopez J, Juan M, et al: Preclinical
development of three novel CARs targeting CD79b for the treatment
of non-Hodgkin's lymphoma and characterization of the loss of the
target antigen. J Immunother Cancer. 12:e0094852024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang L, Li LR and Young KH: New agents and
regimens for diffuse large B cell lymphoma. J Hematol Oncol.
13:1752020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Bhat SA and Czuczman MS: Novel antibodies
in the treatment of non-Hodgkin's lymphoma. Neth J Med. 67:311–321.
2009.PubMed/NCBI
|
|
127
|
Patriarca A and Gaidano G: Investigational
drugs for the treatment of diffuse large B-cell lymphoma. Expert
Opin Investig Drugs. 30:25–38. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Belada D, Kopeckova K, Burgues JM, Stevens
D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, et
al: Safety and efficacy of tafasitamab with or without lenalidomide
added to first-line R-CHOP for DLBCL: The phase 1b First-MIND
study. Blood. 142:1348–1358. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Tarantelli C, Wald D, Munz N, Spriano F,
Bruscaggin A, Cannas E, Cascione L, Gaudio E, Arribas AJ, Manjappa
S, et al: Targeting CD19-positive lymphomas with the antibodydrug
conjugate loncastuximab tesirine: Preclinical evidence of activity
as a single agent and in combination therapy. Haematologica.
109:3314–3326. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lee A: Loncastuximab tesirine: First
approval. Drugs. 81:1229–1233. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Bobrowicz M, Kubacz M, Slusarczyk A and
Winiarska M: CD37 in B cell derived tumors-more than just a docking
point for monoclonal antibodies. Int J Mol Sci. 21:95312020.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Tilly H, Morschhauser F, Sehn LH,
Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M,
Rai S, et al: Polatuzumab vedotin in previously untreated diffuse
large B-cell lymphoma. N Engl J Med. 386:351–363. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Dickinson MJ, Carlo-Stella C, Morschhauser
F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F,
Trněný M, et al: Glofitamab for relapsed or refractory diffuse
large B-cell lymphoma. N Engl J Med. 387:2220–2231. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Thieblemont C, Phillips T, Ghesquieres H,
Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski
R, Jurczak W, et al: Epcoritamab, a novel, subcutaneous CD3×CD20
bispecific T-cell-engaging antibody, in relapsed or refractory
large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin
Oncol. 41:2238–2247. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Bartlett NL, Assouline S, Giri P, Schuster
SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, et
al: Mosunetuzumab monotherapy is active and tolerable in patients
with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv.
7:4926–4935. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ayyappan S, Kim WS, Kim TM, Walewski J,
Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon M, Oh SY, Lim FLWI,
et al: Final analysis of the phase 2 ELM-2 study: Odronextamab in
patients with relapsed/refractory (R/R) diffuse large B-Cell
lymphoma (DLBCL). Blood. 142:4362023. View Article : Google Scholar
|
|
137
|
Brody JD, Jørgensen J, Belada D, Costello
R, Trněný M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, André M, et
al: Epcoritamab plus GemOx in transplant-ineligible
relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial.
Blood. 145:1621–1631. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Viardot A, Goebeler ME, Hess G, Neumann S,
Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C,
Stieglmaier J, et al: Phase 2 study of the bispecific T-cell
engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse
large B-cell lymphoma. Blood. 127:1410–1416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Hou JZ, Nair R, Jacobs R, Kim TM, Cho SG,
Maruyama D, Devata S, Sawalha Y, Yoon DH, Tam CS, et al: Escalating
doses of AZD0486, a novel CD19×CD3 T-cell engager, result in high
complete remissions with rapid clearance of minimal residual
disease in patients with relapsed/refractory follicular lymphoma.
Blood. 144:3412024. View Article : Google Scholar
|
|
140
|
Nair R, Kim TM, Yoon DH, Gaballa S, Cho
SG, Maruyama D, Jacobs R, Devata S, Izutsu K, Sawalha Y, et al:
ABCL-1113: Safety and efficacy of AZD0486, a CD19× CD3 T-Cell
engager, in relapsed or refractory diffuse large B-cell lymphoma.
Clinical Lymphoma Myeloma And Leukemia. 25:S7812025. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Miazek-Zapala N, Slusarczyk A, Kusowska A,
Zapala P, Kubacz M, Winiarska M and Bobrowicz M: The ‘Magic Bullet’
is here? Cell-Based immunotherapies for hematological malignancies
in the twilight of the chemotherapy era. Cells. 10:15112021.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Prasad V: Immunotherapy:
Tisagenlecleucel-the first approved CAR-T-cell therapy:
implications for payers and policy makers. Nat Rev Clin Oncol.
15:11–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Al-Mansour M, Al-Foheidi M and Ibrahim E:
Efficacy and safety of second-generation CAR T-cell therapy in
diffuse large B-cell lymphoma: A meta-analysis. Mol Clin Oncol.
13:332020.PubMed/NCBI
|
|
144
|
Maloney DG: Anti-CD19 CAR T cell therapy
for lymphoma-off to the races! Nat Rev Clin Oncol. 16:279–280.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wang L, Fang C, Kang Q, Huang W, Chen Z,
Zhao W, Wang L, Wang Y, Tan K, Guo X, et al: Bispecific CAR-T cells
targeting CD19/20 in patients with relapsed or refractory B cell
non-Hodgkin lymphoma: A phase I/II trial. Blood Cancer J.
14:1302024. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis
LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T,
Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Spiegel JY, Dahiya S, Jain MD, Tamaresis
J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L,
et al: Outcomes of patients with large B-cell lymphoma progressing
after axicabtagene ciloleucel therapy. Blood. 137:1832–1835.
2021.PubMed/NCBI
|
|
148
|
Neelapu SS, Rossi JM, Jacobson CA, Locke
FL, Miklos DB, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW and Zheng
L: CD19-loss with preservation of other B cell lineage features in
patients with large B cell lymphoma who relapsed post-axi-cel.
Blood. 134:2032019. View Article : Google Scholar
|
|
149
|
Bishop MR, Dickinson M, Purtill D, Barba
P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, et
al: Second-Line tisagenlecleucel or standard care in aggressive
B-cell lymphoma. N Engl J Med. 386:629–639. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Locke FL, Rossi JM, Neelapu SS, Jacobson
CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y,
et al: Tumor burden, inflammation, and product attributes determine
outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood
Adv. 4:4898–4911. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Schuster SJ, Bishop MR, Tam CS, Waller EK,
Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin
JR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse
large B-cell lymphoma. N Engl J Med. 380:45–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Deng Q, Han G, Puebla-Osorio N, Ma MCJ,
Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, et al:
Characteristics of anti-CD19 CAR T cell infusion products
associated with efficacy and toxicity in patients with large B cell
lymphomas. Nat Med. 26:1878–1887. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Haradhvala NJ, Leick MB, Maurer K, Gohil
SH, Larson RC, Yao N, Gallagher KM, Katsis K, Frigault MJ, Southard
J, et al: Distinct cellular dynamics associated with response to
CAR-T therapy for refractory B cell lymphoma. Nat Med.
28:1848–1859. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Tomas AA, Fein JA, Fried S, Flynn JR,
Devlin SM, Fingrut WB, Anagnostou T, Alperovich A, Shah N, Fraint
E, et al: Outcomes of first therapy after CD19-CAR-T treatment
failure in large B-cell lymphoma. Leukemia. 37:154–163. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Yan ZX, Li L, Wang W, OuYang BS, Cheng S,
Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, et al: Clinical efficacy
and tumor microenvironment influence in a dose-escalation study of
anti-CD19 chimeric antigen receptor T cells in refractory B-cell
non-hodgkin's lymphoma. Clin Cancer Res. 25:6995–7003. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng
RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, et al: PD-L1
blockade restores CAR T cell activity through IFN-γ-regulation of
CD163+ M2 macrophages. J Immunother Cancer. 10:e0044002022.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Wang J, Shen K, Mu W, Li W, Zhang M, Zhang
W, Li Z, Ge T, Zhu Z, Zhang S, et al: T cell defects: New insights
into the primary resistance factor to CD19/CD22 cocktail CAR T-Cell
immunotherapy in diffuse large B-cell lymphoma. Front Immunol.
13:8737892022. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Abramson JS, Palomba ML, Gordon LI,
Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG,
Andreadis C, et al: Lisocabtagene maraleucel for patients with
relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001):
A multicentre seamless design study. Lancet. 396:839–852. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Wudhikarn K, Bansal R, Khurana A, Hathcock
MA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB,
Ansell SM and Lin Y: The impact of obesity and body weight on the
outcome of patients with relapsed/refractory large B-cell lymphoma
treated with axicabtagene ciloleucel. Blood Cancer J. 11:1242021.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Jalali S and Ansell SM: The potential role
of glycogen metabolism in diffuse large B-cell lymphoma. Leuk
Lymphoma. 61:1028–1036. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Zhang Y, Lu P, Jin S, Zhang J and Chen X:
Transcriptional activation of SIRT5 by FOXA1 reprograms glycolysis
to facilitate the malignant progression of diffuse large B-cell
lymphoma. Cell Signal. 123:1113562024. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Pacilli A, Calienni M, Margarucci S,
D'Apolito M, Petillo O, Rocchi L, Pasquinelli G, Nicolai R,
Koverech A, Calvani M, et al: Carnitine-acyltransferase system
inhibition, cancer cell death, and prevention of myc-induced
lymphomagenesis. J Natl Cancer Inst. 105:489–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Clozel T, Yang S, Elstrom RL, Tam W,
Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B,
Scott DW, et al: Mechanism-based epigenetic chemosensitization
therapy of diffuse large B-cell lymphoma. Cancer Discov.
3:1002–1019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Martin P, Bartlett NL, Chavez JC, Reagan
JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E, et al:
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in
previously untreated intermediate- to high-risk DLBCL. Blood.
139:1147–1159. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Mathur R, Sehgal L, Havranek O, Köhrer S,
Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE and Samaniego F:
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell
lymphoma to chemotherapeutic drugs. Haematologica. 102:373–380.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Facciotto C, Casado J, Turunen L, Leivonen
SK, Tumiati M, Rantanen V, Kauppi L, Lehtonen R, Leppä S,
Wennerberg K and Hautaniemi S: Drug screening approach combines
epigenetic sensitization with immunochemotherapy in cancer. Clin
Epigenetics. 11:1922019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Chiappinelli KB, Strissel PL, Desrichard
A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et
al: Inhibiting DNA methylation causes an interferon response in
cancer via dsRNA including endogenous retroviruses. Cell.
169:3612017. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Dubovsky JA, Beckwith KA, Natarajan G,
Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY,
Larkin KM, et al: Ibrutinib is an irreversible molecular inhibitor
of ITK driving a Th1-selective pressure in T lymphocytes. Blood.
122:2539–2549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng
PP, Chang BY and Levy R: Therapeutic antitumor immunity by
checkpoint blockade is enhanced by ibrutinib, an inhibitor of both
BTK and ITK. Proc Natl Acad Sci USA. 112:E966–E972. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Deng J, Wang ES, Jenkins RW, Li S, Dries
R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, et al: CDK4/6
inhibition augments antitumor immunity by enhancing T-cell
activation. Cancer Discov. 8:216–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Bouwstra R, He Y, de Boer J, Kooistra H,
Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M,
Huls G, et al: CD47 expression defines efficacy of rituximab with
CHOP in Non-germinal center B-cell (Non-GCB) Diffuse Large B-cell
Lymphoma patients (DLBCL), but not in GCB DLBCL. Cancer Immunol
Res. 7:1663–1671. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Chao MP, Alizadeh AA, Tang C, Myklebust
JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al:
Anti-CD47 antibody synergizes with rituximab to promote
phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142:699–713.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Kravitz CJ, Yan Q and Nguyen DX:
Epigenetic markers and therapeutic targets for metastasis. Cancer
Metastasis Rev. 42:427–443. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Duell J, Abrisqueta P, Andre M, Gaidano G,
Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ,
Menne T, et al: Tafasitamab for patients with relapsed or
refractory diffuse large B-cell lymphoma: Final 5-year efficacy and
safety findings in the phase II L-MIND study. Haematologica.
109:553–566. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Caimi PF, Ai W, Alderuccio JP, Ardeshna
KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, et
al: Loncastuximab tesirine in relapsed or refractory diffuse large
B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm,
phase 2 trial. Lancet Oncol. 22:790–800. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Song Y, Tilly H, Rai S, Zhang H, Jin J,
Goto H, Terui Y, Shin HJ, Kim WS, Cao J, et al: Polatuzumab vedotin
in previously untreated DLBCL: An Asia subpopulation analysis from
the phase 3 POLARIX trial. Blood. 141:1971–1981. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Sehn LH, Hertzberg M, Opat S, Herrera AF,
Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, et
al: Polatuzumab vedotin plus bendamustine and rituximab in
relapsed/refractory DLBCL: Survival update and new extension cohort
data. Blood Adv. 6:533–543. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Abramson JS, Ku M, Hertzberg M, Huang HQ,
Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, et al:
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus
rituximab-GemOx for relapsed or refractory diffuse large B-cell
lymphoma (STARGLO): A global phase 3, randomised, open-label trial.
Lancet. 404:1940–1954. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Jaeger U, Worel N, McGuirk JP, Riedell PA,
Fleury I, Du Y, Han X, Pearson D, Redondo S and Waller EK: Safety
and efficacy of tisagenlecleucel plus pembrolizumab in patients
with r/r DLBCL: Phase 1b PORTIA study results. Blood Adv.
7:2283–2286. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Ernst M, Oeser A, Besiroglu B,
Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt
LJ, Skoetz N and Goldkuhle M: Chimeric antigen receptor (CAR)
T-cell therapy for people with relapsed or refractory diffuse large
B-cell lymphoma. Cochrane Database Syst Rev.
9:CD0133652021.PubMed/NCBI
|
